摘要
目的探讨Raf激酶抑制蛋白(RKIP)表达与非小细胞肺癌(NSCLC)临床病理参数及预后的关系。方法应用免疫组化SP法检测83例NSCLC患者癌组织和65例正常肺组织中RKIP蛋白的表达。结果 NSCLC癌组织中RKIP蛋白表达的阳性率20.5%(17/83),正常肺组织RKIP蛋白表达的阳性率64.6%(42/65)。RKIP蛋白阳性与肿瘤组织分化程度、临床分期、生存时间以及有无淋巴结和远处转移相关(P<0.05)。结论 RKIP蛋白表达与NSCLC发展有关,RKIP可能成为治疗肺癌侵袭转移的新靶点。
Objective To explore the correlation between the expression of raf kinase inhibitor protein (RKIP) and clinieopathological parameters and prognoses of patients with non-small-cell lung cancer (NSCLC). Methods Immunohistochemical staining (SP) was used to determine the expression of RKIP in 83 cases of lung cancer tissues and 65 cases of normal lung tissues. All the patients were followed-up from 3 months to 60 months. Results The positive rates of RKIP expression were 20.5% ( 17/83 ) ,64.6% (42/65) in NSCLC and normal lung tissues respectively. The expression of RKIP was closely correlated with the differentiation degree of tumor tissue, clinical staging, patients'survival time,lymph node metastasis ( P 〈 0.05). Conclusion The expression of RKIP is correlated with development of NSCLC, so RKIP may be a new target to treat the invasion and metastasis of lung Cancer.
出处
《河北医药》
CAS
2011年第22期3371-3373,共3页
Hebei Medical Journal
关键词
RAF激酶抑制蛋白
肺肿瘤
免疫组织化学
染色
raf kinase inhibitor protein
lung neoplasms
immunohistochemistry
staining